Clinical Utility of Various Formulations of Calcipotriene and Betamethasone Dipropionate for the Treatment of Plaque Psoriasis in Patients Aged 12 Years or Older
Kamila Kędra,Adam Reich
DOI: https://doi.org/10.2147/dddt.s240867
IF: 4.3188
2024-12-08
Drug Design Development and Therapy
Abstract:Kamila K&eogondra, 1, 2 Adam Reich 1 1 Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, 35-055, Poland; 2 Doctoral School, University of Rzeszow, Rzeszow, Poland Correspondence: Adam Reich, Email Plaque-type psoriasis is a chronic immune-mediated inflammatory skin disease of uncertain etiology, significantly impacting patient well-being. This chronic condition not only contributes to stigmatization and mental health challenges but also poses an independent risk for cardiovascular and other comorbid diseases. Affecting approximately 60 million people globally, psoriasis manifests primarily as mild-to-moderate disease in about 80% of cases, where topical therapy is pivotal. The most commonly used topical antipsoriatic therapy involves a combination of vitamin D3 analog (calcipotriene – Cal) and a synthetic potent corticosteroid (betamethasone dipropionate – BD). Various formulations of Cal/BD, including ointment, gel (topical suspension), and aerosol foam, have been approved by the US Food and Drug Administration (FDA). The cream based on the PAD (Polyaphron Dispersion) technology is another formulation of this combination drug, expanding the therapeutic options for patients with psoriasis. This article summarizes the most relevant published studies concerning the efficacy and safety of different calcipotriol and betamethasone formulations treating of plaque-type psoriasis in patients aged 12 or older. Keywords: psoriasis vulgaris, calcipotriene, betamethasone dipropionate, topical therapy, vitamin D derivatives, corticosteroids Plaque-type psoriasis is a chronic, immune-mediated, inflammatory skin disease of uncertain etiology with a great impact on patient's well-being. 1 Psoriasis, through lowered self-esteem, feeling of stigmatization, and loneliness, leads to difficulties in interpersonal relationships and withdrawal from many activities, which negatively affects patients' quality of life (QoL). Moreover, psoriasis burdens not only the patient's mental sphere but also has been identified as an independent contributor to the cardiovascular risk due to persistent systemic inflammation. The disease has been linked to various comorbidities, such as arterial hypertension, diabetes, Crohn's disease, dyslipidemia and cerebrovascular disease. 1 Psoriasis affects approximately 60 million individuals worldwide and its prevalence in the adult population ranges between 0.09% and 11.4% depending of the studied populations. 2 Approximately 80% of patients with psoriasis present with mild-to-moderate disease, for which topical therapy is the cornerstone of treatment. Alternative therapeutic options, particularly in more severe cases, include systemic non-biological treatments, biologics and phototherapy, depending on the patient's preferences, the severity of the disease and the success of previous therapies. 3 However, access to biological treatment remains challenging due to the high costs associated with this therapy. 4 In addition, as the use of systemic medications registered for the treatment of psoriasis, such as methotrexate, cyclosporine, acitretin, or apremilast, carries the risk of potential side effects and requires regular monitoring, topical therapy is often favored as the initial therapeutic option. 5 So far, many patients perceive existing topical treatments as ineffective, uncomfortable, and time-consuming to apply. Therefore, non-compliance poses a significant obstacle to achieving treatment success. Since there is currently no cure of psoriasis, a compelling need exists for ongoing enhancement of topical drug formulations to achieve both high efficacy and satisfactory user-friendliness. 6 There are numerous topical treatments for psoriasis, available in different formulations such as lotions, creams, ointments, gels and foams. The selection of a topical agent from the wide range of options depends on the course of the disease itself (including the morphological variant and location of psoriatic lesions) as well as patients' preferences. 7 Topical therapies for psoriasis include: topical corticosteroids, calcineurin inhibitors (used off-label), vitamin D3 analogues (such as calcitriol, calcipotriol, tacalcitol), tazarotene and recently approved by the US Food and Drug Administration (FDA): tapinarof (Aryl hydrocarbon receptor, AhR, agonist) and roflumilast (phosphodiesterase 4, PDE4, inhibitor). 7–9 According to the American, Canadian and European treatment guidelines, the fixed-dose combination of calcipotriol (Cal), a vitamin D3 analogue, and betamethasone dipropionate (BD), a potent corticosteroid, are recommended as the initial therapy for mild-to-moderate psoriasis. The combination of these -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal